A Phase 2 interventional study of HP515 10 mg Tablet and Placebo of HP515 10 mg Tablet in NAFLD (Non-alcoholic Fatty Liver Disease), sponsored by Hinova Pharmaceuticals Inc.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Hinova Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.
Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 62nd largest by planned enrollment of the 89 interventional ones that give a count, is one of 11 that started in 2025, is one of 20 in phase 2, reaches primary completion later than 25 of the 52 other live ones, and was the 132nd registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Liu Yan · Sites in China
Ages 18–65
The Affiliated Hospital of Hangzhou Normal University · Sites in China
Ages 65–100 · Healthy volunteers
Hudson Biotech · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Argentina and 31 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 22 · Phase 3 7 · Phase 4 11
First in 2004; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 112 across the 89 interventional studies, 740 across the 54 observational. Of the 63 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 143 have an industry lead sponsor. The 10 most frequent:
Hinova Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Hinova Pharmaceuticals Inc. has 1 study filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Non-alcoholic Fatty Liver Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449833Zhujiang HospitalEffect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD | 2026-11 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
| NCT06569524Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) | 2026-12 |
| NCT07099118Sunshine Lake Pharma Co., Ltd.A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects | 2026-12-30 |
| NCT06717828Fujian Provincial HospitalThe Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary objectives:
Exploratory objective:
The study includes a screening period of 4 weeks, a treatment period of 12 weeks, and a safety follow-up period of 4 weeks.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical trial conducted in participants with non-alcoholic fatty liver disease.
The trial includes a screening period (D-28 to D-1), a treatment period (Week 1 to Week 12), and a safety follow-up period (Week 13 to Week 16).
Eligible participants are randomized based on stratification factors \[D1 body weight \<80 kg vs ≥80 kg]. Participants with body weight \<80 kg are randomized in a 2:2:1 ratio to HP515 40 mg group, HP515 50 mg group, and placebo group. Participants with body weight ≥80 kg are randomized in a 2:1 ratio to HP515 60 mg group and placebo group. Each HP515 group enrolls 20 participants, totaling 60 participants, and the placebo group enrolls 20 participants, with a total of 80 participants enrolled.
All participants receive 12 weeks of medication, and the entire study process includes evaluation of efficacy and safety for all participants, as well as evaluation of targeted biomarkers.
All participants provided Pop-PK blood samples on an empty stomach before morning dosing at the end of Weeks 2, 6, 8, 10, and 12. Intensive blood sampling was performed for all participants completing 4 weeks of treatment or withdrawing early before the end of Week 4. Participants who completed the early withdrawal visit after at least 1 week of continuous dosing and did not discontinue medication prior to the in-person visit were encouraged to complete intensive PK sampling. ≥MRI-PDFF and FibroScan examinations were performed during the screening period, at 12 weeks of treatment, and at early withdrawal visits (requiring a minimum of 6 weeks of medication duration). Participants who completed 12 weeks of treatment completed the treatment phase, while those who completed the 16-week safety follow-up completed the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two HP515 20 mg Tablets +Two Placebos of HP515 10mg Tablets
Drug: Placebo of HP515 10 mg Tablet · Drug: HP515 20 mg Tablet
Two HP515 20mg Tablets + One HP515 10mg Tablet + One Placebo of HP515 10mg Tablet
Drug: HP515 10 mg Tablet · Drug: Placebo of HP515 10 mg Tablet · Drug: HP515 20 mg Tablet
Two HP515 20mg Tablets + Two HP515 10mg Tablets
Drug: Placebo of HP515 10 mg Tablet · Drug: HP515 20 mg Tablet
Two Placebos of HP515 20mg Tablet +Two Placebos of HP515 10mg Tablet
Drug: Placebo of HP515 10 mg Tablet · Drug: Placebo of HP515 20mg Tablet
Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C. HP515 10mg Tablet, qd
Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C. Placebo of HP515 10 mg Tablet ,qd , 12 weeks.
Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C; HP515 20 mg Tablet, qd,12 weeks
Provided by provided by Hinova Pharmaceuticals Inc .Storage: Protect from light, keep sealed, store at ≤25°C; Placebo of HP515 20 mg Tablet, qd,12 weeks
The relative change in liver fat fraction from the baseline by magnetic resonance proton density fat fraction (MRI-PDFF).
Relative change from baseline is calculated for each subject as 100% x \[(Week 12 Value - Baseline Value)/Baseline Value\].
Time frame: Baseline and Week 12.
The absolute change in liver fat fraction from the baseline by magnetic resonance proton density fat fraction (MRI-PDFF).
Absolute change from baseline is calculated for each subject as \[(Week 12 Value - Baseline Value)\].
Time frame: Baseline and Week 12.
At the 12-week treatment period, through MRI-PDFF measurement, the proportion of participants whose liver fat fraction decreased by more than 30% or 50%.
Proportion of subjects with ≥30% or 50% relative reduction in liver fat content by MRI-PDFF at Week 12
Time frame: Week 12.
The percentage changes of blood lipid
Percent change from baseline of low-density lipoprotein cholesterol (LDL-C)
Time frame: Baseline, up to 12 weeks.
Number and Percentage of participants with any Treatment Emergent adverse events as assessed by CTCAE v5.0.[Time Frame: up to 16 weeks.]
Safety of HP515 based on Adverse Events and Changes in Laboratory Values、vital signs, physical examination, 12-lead electrocardiogram.
Time frame: Up to 16 weeks.
Assessment of pharmacokinetic parameters of HP515 : Maximum concentration (Cmax)
Time frame: Baseline, up to 12 weeks
Assessment of pharmacokinetic parameters of HP515 : area under the concentration-time curve (AUC)
Time frame: Base line and up to 12 weeks
Assessment of pharmacokinetic parameters of HP515: Time to maximum concentration (Tmax)
Time frame: Base line and up to 12 weeks
Plan to share: No — All the unpublished information provided by the sponsor to the researchers and any data generated from this trial are confidential and are exclusive to the sponsor. The researchers agree to keep this information confidential and use it only to complete this study. Such information may not be used for any other purpose without the written consent of the sponsor. The trial results will be presented in the form of a clinical trial report (CSR), which includes the data from all participating units. Any data derived from the trial and involving copyright protection belong to the sponsor. The sponsor has the right to publish these materials and information.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 10 months after the start.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 10 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Hinova Pharmaceuticals Inc.